DEVELOPING A REGIONAL CANCER CENTER IN SOUTH CAROLINA

南卡罗来纳州医科大学（MUSC）希望为 发展综合性癌症中心，Hollings肿瘤中心 (HOC)以降低该地区癌症的发病率和死亡率。 MUSC是 为实现这一目标进行了重大投资，建造了一座新大楼， 致力于癌症研究以及翻新额外的医院区域 治疗癌症 MUSC的整个行政结构致力于 这在学术方面和基础设施建设方面都有很大的发展。 据统计，南卡罗来纳州领先或几乎领先于各州， 六种重要癌症的死亡率 该地区呈现出 这是一个对服务不足和少数群体产生影响的绝佳机会 人口。 外联和预防是主要组成部分， 可以实现具体目标。 这些措施包括：1）延长 早期区域SEER兼容肿瘤登记， 地理区域; 2）与联合国建立的初级预防联盟和方案 地区三叉戟卫生区和国务院卫生和 环境控制; 3）与已证明的少数群体的外联活动 （4）大量少数民族患者的进入， 合作组试验; 5）扩大乳腺癌的早期筛查， 子宫颈癌，以充分融入 通过HOC跟进服务; 6）启动适当的咨询， 以预防为主的职业教育。 该机构的目标是增加其癌症研究基地， 基础科学和临床领域，特别强调以下领域 翻译多学科方法。 中心招聘 主任与一个主要研究小组的合作已进入最后阶段。 五个空缺的系主任职位优先用于 各种癌症特定或相关学科。 研究项目是 在基本的分子和生物化学领域启动和规划。 最近 MUSC在干细胞生物学方面的进展是唯一的挑衅， 骨髓移植和基因治疗的新机会。 尖端的单克隆抗体技术，包括单链和 免疫毒素将被纳入临床试验。 这两 活动涉及与四个主要NCI正在进行或刚刚开始的合作 实验室主任 必须探索最佳治理模式， HOC的身份。 关于特别行政区的具体权力和特权的计划 董事会正在讨论，包括中心和 MUSC的所有其他癌症相关项目。 在所有新程序开发中， 目标是组织三个工作组， 区域规划人员与关键的外部咨询专家和其他 顾问。 目前正在计划一次具有重要财政基础的集会 成功启动和发展的HOC，这是第一个 在MUSC的整个行政结构的商定的优先事项。 致力于MUSC的几个独特的计划机会正在瞄准 癌症活动。

The Medical University of South Carolina (MUSC) wishes to plan for the development of a comprehensive cancer center, Hollings Oncology Center (HOC) to reduce the morbidity and mortality of cancer in its area. MUSC is making a major investment towards this goal by constructing a new building devoted to cancer research as well as renovating additional hospital areas for cancer. The entire administrative structure of MUSC is committed to this build-up both in academic terms and in infrastructure development. Statistically, South Carolina leads or almost leads the states in the mortality of six significant cancers. This region presents an extraordinary opportunity to make an impact on underserved and minority populations. Outreach and prevention are major components by which specific objectives can be realized. These include: 1) an extension of the incipient regional SEER-compatible tumor registry to the entire geographic area; 2) coalition and programs in primary prevention with the regional Trident Health District and State Dept. of Health and Environmental Control; 3) outreach activities with proven minority organization; 4) entering of substantial numbers of minority patients and cooperative group trials; 5) expanding early screening for breast and cervical cancer to underserved populations with integration into full- service follow through via HOC; 6) initiating appropriate consultation and prevention-oriented professional education. The institution has the goal of increasing its cancer research base in basic science and clinical areas, with particular stress in the areas of translational multidisciplinary approaches. Recruitment for a center director concomitant with a major research group is into final stages. Five vacant department chair positions are targeted preferentially for various cancer specific or related disciplines. Research programs are to be initiated and planned in basic molecular and biochemical areas. Recent advances at MUSC in stem cell biology are uniquely provocative to develop novel opportunities in bone marrow transplantation and gene therapy. Cutting edge monoclonal antibody technology including single chains and immunotoxins are to be integrated into clinical trials. Both of these activities involve ongoing or incipient collaborations with four major NCI laboratory chiefs. Optimal governance models have to be explored for the final administrative identity of HOC. Plans for specific authorities and prerogatives for the director are being discussed including the interface between the center and all other cancer-related programs at MUSC. In all new program development, the goal is to organize three working groups comprised of internal and regional planners with key external advisory experts and additional consultants. An assembly of a significant financial base is being planned for successful start-up and development of the HOC which is the number one agreed-upon priority of the entire administrative structure at MUSC. Several unique program opportunities dedicated to MUSC are being targeted to cancer activities.